Back to search

Virginia Commonwealth University

Anti-Tumor Functions of Sphingosine Kinase 1 and Sphingosine Kinase 2 in Breast Cancer Development

Abstract

dc:description.abstract

Bioactive sphingolipid metabolite sphingosine-1‐phosphate (S1P) circulating levels have been implicated in breast cancer (BC) progression. BCs usually respond to 17β-Estradiol (E2) through canonical receptor ERα66 for genomic effects, however, E2 also triggers rapid, non-genomic responses. E2 has been shown to activate sphingosine kinase 1 (SphK1), increasing S1P for S1P receptors signaling important for BC. The E2 receptor activating SphK1 has not been identified. We demonstrate triple negative BC cells, expressing only novel ERα splice variant ERα36, E2-induced SphK1 activation for S1P secretion. Tamoxifen, first-line BC endocrine therapy, an ERα66 antagonist but ERα36 agonist, activates SphK1 and increases S1P secretion in tamoxifen resistant BCs. Furthermore, tamoxifen resistance correlates with increased SphK1 and ERα36 expression in patients. Therefore, targeting ERα36 and SphK1 axis may be a therapeutic option to circumvent endocrine resistance and improve patient outcome. In contrast, surprisingly, deletion or inhibition of the other isoenzyme that produces S1P, sphingosine kinase 2 (SphK2), shown to greatly increases circulating levels of S1P, markedly suppressed syngeneic triple-negative BC growth and pulmonary metastasis. In these lungs, immunosuppressive PMN-MDSCs and Tregs decreased and immunostimulant T effector, NK and M1 macrophages increased, creating a hostile microenvironment. Intriguingly, SphK2 inhibition or deletion increased lung ceramide and tumor suppressor p53 expression to decrease the genetic transformation of normal fibroblast to cancer-associated fibroblasts (CAF), restraining the CAF tumor-promoting secretome and creating an active anti-tumor microenvironment. This work highlights SphK2/p53 axis in stromal fibroblasts and suggests targeting SphK2 may pave way for development of novel targeted immunotherapeutics to boost anti-cancer immunity.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Biochemistry

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Maczis, Melissa A
  • <p>https://orcid.org/0000-0002-8610-2475</p>
Contributors dc:contributor
  • Sarah Spiegel, PhD
  • Tomasz K. Kordula, PhD
  • Jennifer Koblinski, PhD
  • Paula D Bos, PhD
  • Xianjun Fang, PhD

Subjects

dc:subject × 11

Rights

dc:rights
Statement dc:rights
  • © Melissa A. Maczis

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
Virginia Commonwealth University
Base URL
scholarscompass.vcu.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Maczis, Melissa A; <p>https://orcid.org/0000-0002-8610-2475</p>. Anti-Tumor Functions of Sphingosine Kinase 1 and Sphingosine Kinase 2 in Breast Cancer Development. Dissertation thesis, https://doi.org/10.25772/527S-KA95